

Published by the American Association for the Advancement of Science (AAAS), Science serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in Science—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

Membership/Circulation

Director: Michael Spinella

Deputy Director: Marlene Zendell

Member Services: Rebecca Dickerson, Manager; Mary Curry, Supervisor; Pat Butler, Helen Williams, Laurie Baker, Representatives

Marketing: Dee Valencia, Manager; Jane Pennington, Europe Manager; Hilary Baar, Associate; Angela Mumeka, Coordinator

Business and Finance: Jacquelyn Roberts, *Manager*, Robert Smariga, *Assistant Manager* Administrative Assistant: Nina Arauio de Kobes

Science Member Services

Marion, Ohio: 800-347-6969;

Washington, DC: 202-326-6417 Other AAAS Programs: 202-326-6400

Advertising and Finance

Associate Publisher: Beth Rosner Advertising Sales Manager: Susan A. Meredith Recruitment Advertising Manager: Janis Crowley Advertising Business Manager: Deborah Rivera-Wienhold

Finance: Randy Yi, *Senior Analyst;* Shawn Williams, *Analyst* Marketing: John Meyers, *Manager;* Allison Pritchard,

Associate Traffic Manager: Tina Turano Recruitment: Terri Seiter, Assistant Manager; Dan Moran, Traffic Manager; Debbie Cummings, Celeste Wakefield, Angela Wheeler, Sales Reprints Manager: Corrine Harris

Permissions Manager: Arlene Ennis Sales Associate: Carol Maddox

ADVERTISING SALES: East Coast/E. Canada: Richard Teeling, 201-904-9774, FAX 201-904-9701 • Southeast: Mark Anderson, 305-856-8567, FAX 305-856-1056 • Midwest: Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • West Coast/W. Canada: Neil Boylan, 415-673-9265, FAX 415-673-9267 • UK, Scandinavia, France, Italy, Belgium, Netherlands: Andrew Davies, (44) 457-838-519, FAX (44) 457-838-898 • Germany/Switzerland/ Austria: Tracey Peers, (44) 270-760-108, FAX (44) 270-755-597 • Japan: Mashy Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852

Recruitment: 202-326-6555, FAX 202-682-0816 European Recruitment: AnneMarie Vis, (44) 0223-302067, FAX (44) 0223-302068

Australia/New Zealand Recruitment: Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100 Send materials to *Science* Advertising, 1333 H Street,

NW, Washington, DC 20005.

Information for Contributors appears on pages 37–39 of the 7 January 1994 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005.

Internet addresses: science_editors@aaas.org (for general editorial queries); science_letters@aaas.org (for letters to the editor); science_reviews@aaas.org (for returning manuscript reviews)

LETTERS

Colon Cancer Screening

In the article "Gene defect identified in common hereditary colon cancer" (Research News, 10 Dec., p. 1645), Francis Collins, director of the National Center for Human Genome Research at the National Institutes of Health (NIH), is quoted as saying, "This is a circumstance where a strong case can be made for presymptomatic DNA testing in the general population."

Hereditary nonpolyposis colon cancer (HNPCC) is a dominantly inherited condition of late onset with a high penetrance. Case finding after family investigation therefore offers an efficient way of recognizing most of the people at risk in the community. Case finding will be much easier than with Huntington's disease or myotonic dystrophy because colon cancers are subjected to pathological examination, and it should be simple to combine this with an assessment of mutations in DNA extracted from a blood sample to identify those patients with colon cancer resulting from mutations in the gene on chromosome 2. (Of course improvement in mutation detection methods will be needed to cope with the volume of work.) Subsequent studies among family members of those shown to have chromosome 2 mutations should vield positive results in 50% of those tested.

If one uses the figures quoted in the article, the first step of this procedure would have a 15% yield and the second step a 50% yield, compared with the 1 in 200 frequency of positive tests to be expected in whole community screening. Only a high mutation rate, unlikely in a disease of postreproductive onset, could negate this logic. A great additional advantage is that all testing would be performed on persons who already have the disease or who are concerned about the disease because a close relative is suffering from it. In this country there is a high level of concern about the possibility of overzealous application of genetic testing, especially on a population-wide basis, and while I share Collins' enthusiasm, one must keep in mind how best to establish efficient preventive health measures without alarming the general public.

David M. Danks Director, Murdoch Institute for Research into Birth Defects, Royal Children's Hospital, Flemington Road, Parkville, Melbourne 3052, Australia

SCIENCE • VOL. 264 • 1 APRIL 1994

Response: Danks is quite right to raise concern about the quotation attributed to me, which could easily be misinterpreted. While presymptomatic screening of the general population for HNPCC may not be completely out of the question in the long term, I agree it would be premature to consider such screening at the present time, given the current state of our ignorance. In fact, the National Advisory Council on Human Genome Research (which I chair) has recently issued a statement (1) that presymptomatic testing for MSH2 mutations should at present be offered only to high-risk individuals, and even then only in a closely monitored research environment. The joint NIH-Department of Energy Working Group on Ethical, Legal, and Social Implications of the Human Genome Project has endorsed this statement.

Research studies are urgently needed to clarify the technical issues surrounding HNPCC mutation detection, to assess the penetrance of mutant alleles, and to illuminate the complexities of patient education and genetic counseling. A Request for Applications has just been issued by the National Center for Human Genome Research, the National Cancer Institute, the National Institute of Nursing Research, and the National Institute of Mental Health to solicit research projects designed to clarify some of these issues (2).

Certainly the initial clinical consequences of testing are likely to be most profound in individuals with a strong family history of colon cancer. But it would be surprising if HNPCC alleles of lower penetrance were not also uncovered. An individual carrying such an allele might still be at considerably elevated risk from colon cancer (and could thus greatly benefit from increased medical surveillance), but might not necessarily have a dramatic family history or a relative who came to pathologic and DNA examination.

These complex scientific issues, as well as questions of cost-effectiveness and the feasibility of large-scale genetic testing and counseling, will have to be satisfactorily addressed before consideration of general population screening for colon cancer. The reasoned and thoughtful input of many groups—geneticists, oncologists, primary care physicians, ethicists, genetic counselors, health economists, and especially consumers—will be necessary if we are to negotiate these difficult waters successfully.

Francis S. Collins Director, National Center for Human Genome Research, National Institutes of Health, Bethesda, MD 20892, USA

References

- 1. National Advisory Council for Human Genome Research, J. Am. Med. Assoc. 217, 785 (1994).
- NIH Guide Grants Contracts 23 (no. 5) (4 February 1994).

Plutonium's Existence

The article "No easy way to shackle the nuclear demon" (Science after the Cold War, 4 Feb., p. 629) by Gary Taubes states that plutonium is an element that did not exist on the planet before it was made in the laboratory in 1940. Plutonium (²⁴⁴Pu) has existed in nature at low concentrations for eons (1). Primordial ²³⁹Pu would have long since decayed into ²³⁵U. Yet in uranium-bearing minerals small quantities of ²³⁹Pu are formed by the action of natural neutrons on ²³⁸U to

form ²³⁹U, which forms ²³⁹Np through beta decay. After another beta emission, the ²³⁹Np becomes ²³⁹Pu (2). In fact, we now know the isotope ²³⁹Pu was formed in natural reactors in western Africa almost 2 billion years ago (3).

Plutonium (later shown to be ²³⁸Pu) was first isolated in trace quantities by Glenn T. Seaborg and his co-workers at the University of California, Berkeley, on 24 February 1941 (4). It was not until spring 1941 that ²³⁹Pu, the fissile stuff of nuclear bombs, was isolated and identified at Berkeley. The element with atomic number 94 was not named plutonium until March 1942.

The article also states that all the isotopes of Pu are fissionable. However, of the 16 isotopes of Pu (5), only 239 Pu is fissile and used in nuclear bombs. The shorter-lived 241 Pu is fissile, but not of importance to nuclear bombs.

Finally, the article refers to tritium as being "short-lived." Actually, its 12.35-year physical half-life, although short by comparison with that of 239 Pu, is relatively long compared with the life-span of human subjects. For example, after 30 years, about 19% of tritium atoms still remain.

C. R. Richmond Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA

References


- 1. D. C. Hoffman et al., Nature 234, 132 (1971).
- G. T. Seaborg and M. L. Pearlman, in *The Transuranium Elements*, G. T. Seaborg, J. J. Katz, W. M. Manning, Eds. (McGraw-Hill, New York, 1949).
 G. A. Cowan, *Sci. Am.* 235, 36 (July 1976).

- G. A. Cowaii, *oc. An. 255*, 36 (July 1976).
 G. T. Seaborg, in *Radiobiology of Plutonium*, B. J. Stover and W. S. S. Jee, Eds. (J. W. Press, University of Utah, Salt Lake City, 1972), pp. 1–21.
- C. M. Lederer, J. M. Hollander, I. Pearlman, *Table of the Isotopes* (Wiley, New York, ed. 6, 1967).

Fusion Confusion

James Glanz, in his article "DOE lifts the veil of secrecy from laser fusion" (News & Comment, 17 Dec., p. 1811), refers to "Project Matterhorn" as the early name of the U.S. magnetic fusion program. That was the name of the (originally classified) magnetic fusion program at Princeton University, which became the Princeton Plasma Physics Laboratory. "Project Sherwood" was the overall name for the U.S. fusion program (1), which in the 1950s and 1960s was virtually all based on magnetic confinement.

The Princeton fusion program inherited its name (and some key players) from an earlier Project Matterhorn, which under the direction of John Archibald Wheeler studied some



Come see us at AACR, Booth #528 Circle Reader Service No. 23